November 6, 2020 – As part of an ongoing collaboration between the U.S. Department of Health and Human Services (HHS) and the U.S. Department of Defense (DOD), the two departments awarded Hologic, Inc. a $119 million contract to establish additional domestic production to increase diagnostic testing capacity for SARS-CoV-2.
This investment will enable Hologic to expand production capacity for COVID-19 tests in its facilities in Wisconsin, Maine, and California, increasing their production capacity to 13 million COVID-19 tests per month by January 2022.
Hologic’s Panther Fusion SARS-CoV-2 Assay and Aptima SARS-CoV-2 Assay received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration in March 2020 and May 2020, respectively.
The tests run on the Company’s fully automated Panther Fusion and Panther systems. More than 2,000 of these systems have been installed in clinical diagnostic laboratories around the world, including in all 50 U.S. states.